Genmab A/S (GMAB)
- Previous Close
27.46 - Open
28.09 - Bid 28.11 x 100
- Ask 28.16 x 200
- Day's Range
27.91 - 28.18 - 52 Week Range
26.32 - 42.72 - Volume
339,609 - Avg. Volume
559,350 - Market Cap (intraday)
18.268B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
29.63 - EPS (TTM)
0.95 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
41.15
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
www.genmab.comRecent News: GMAB
Performance Overview: GMAB
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GMAB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GMAB
Valuation Measures
Market Cap
17.82B
Enterprise Value
13.89B
Trailing P/E
28.99
Forward P/E
24.57
PEG Ratio (5yr expected)
1.19
Price/Sales (ttm)
7.66
Price/Book (mrq)
3.93
Enterprise Value/Revenue
0.84
Enterprise Value/EBITDA
2.33
Financial Highlights
Profitability and Income Statement
Profit Margin
26.42%
Return on Assets (ttm)
10.17%
Return on Equity (ttm)
14.78%
Revenue (ttm)
16.47B
Net Income Avi to Common (ttm)
4.35B
Diluted EPS (ttm)
0.95
Balance Sheet and Cash Flow
Total Cash (mrq)
28.14B
Total Debt/Equity (mrq)
2.44%
Levered Free Cash Flow (ttm)
5.29B